Cargando…
Complexity of progranulin mechanisms of action in mesothelioma
BACKGROUND: Mesothelioma is an aggressive disease with limited therapeutic options. The growth factor progranulin plays a critical role in several cancer models, where it regulates tumor initiation and progression. Recent data from our laboratories have demonstrated that progranulin and its receptor...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9720952/ https://www.ncbi.nlm.nih.gov/pubmed/36471440 http://dx.doi.org/10.1186/s13046-022-02546-4 |
_version_ | 1784843659051532288 |
---|---|
author | Ventura, Elisa Xie, Christopher Buraschi, Simone Belfiore, Antonino Iozzo, Renato V. Giordano, Antonio Morrione, Andrea |
author_facet | Ventura, Elisa Xie, Christopher Buraschi, Simone Belfiore, Antonino Iozzo, Renato V. Giordano, Antonio Morrione, Andrea |
author_sort | Ventura, Elisa |
collection | PubMed |
description | BACKGROUND: Mesothelioma is an aggressive disease with limited therapeutic options. The growth factor progranulin plays a critical role in several cancer models, where it regulates tumor initiation and progression. Recent data from our laboratories have demonstrated that progranulin and its receptor, EphA2, constitute an oncogenic pathway in bladder cancer by promoting motility, invasion and in vivo tumor formation. Progranulin and EphA2 are expressed in mesothelioma cells but their mechanisms of action are not well defined. In addition, there are no data establishing whether the progranulin/EphA2 axis is tumorigenic for mesothelioma cells. METHODS: The expression of progranulin in various mesothelioma cell lines derived from all major mesothelioma subtypes was examined by western blots on cell lysates, conditioned media and ELISA assays. The biological roles of progranulin, EphA2, EGFR, RYK and FAK were assessed in vitro by immunoblots, human phospho-RTK antibody arrays, pharmacological (specific inhibitors) and genetic (siRNAs, shRNAs, CRISPR/Cas9) approaches, motility, invasion and adhesion assays. In vivo tumorigenesis was determined by xenograft models. Focal adhesion turnover was evaluated biochemically using focal adhesion assembly/disassembly assays and immunofluorescence analysis with focal adhesion-specific markers. RESULTS: In the present study we show that progranulin is upregulated in various mesothelioma cell lines covering all mesothelioma subtypes and is an important regulator of motility, invasion, adhesion and in vivo tumor formation. However, our results indicate that EphA2 is not the major functional receptor for progranulin in mesothelioma cells, where progranulin activates a complex signaling network including EGFR and RYK. We further characterized progranulin mechanisms of action and demonstrated that progranulin, by modulating FAK activity, regulates the kinetic of focal adhesion disassembly, a critical step for cell motility. CONCLUSION: Collectively, our results highlight the complexity of progranulin oncogenic signaling in mesothelioma, where progranulin modulate functional cross-talks between multiple RTKs, thereby suggesting the need for combinatorial therapeutic approaches to improve treatments of this aggressive disease. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13046-022-02546-4. |
format | Online Article Text |
id | pubmed-9720952 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-97209522022-12-06 Complexity of progranulin mechanisms of action in mesothelioma Ventura, Elisa Xie, Christopher Buraschi, Simone Belfiore, Antonino Iozzo, Renato V. Giordano, Antonio Morrione, Andrea J Exp Clin Cancer Res Research BACKGROUND: Mesothelioma is an aggressive disease with limited therapeutic options. The growth factor progranulin plays a critical role in several cancer models, where it regulates tumor initiation and progression. Recent data from our laboratories have demonstrated that progranulin and its receptor, EphA2, constitute an oncogenic pathway in bladder cancer by promoting motility, invasion and in vivo tumor formation. Progranulin and EphA2 are expressed in mesothelioma cells but their mechanisms of action are not well defined. In addition, there are no data establishing whether the progranulin/EphA2 axis is tumorigenic for mesothelioma cells. METHODS: The expression of progranulin in various mesothelioma cell lines derived from all major mesothelioma subtypes was examined by western blots on cell lysates, conditioned media and ELISA assays. The biological roles of progranulin, EphA2, EGFR, RYK and FAK were assessed in vitro by immunoblots, human phospho-RTK antibody arrays, pharmacological (specific inhibitors) and genetic (siRNAs, shRNAs, CRISPR/Cas9) approaches, motility, invasion and adhesion assays. In vivo tumorigenesis was determined by xenograft models. Focal adhesion turnover was evaluated biochemically using focal adhesion assembly/disassembly assays and immunofluorescence analysis with focal adhesion-specific markers. RESULTS: In the present study we show that progranulin is upregulated in various mesothelioma cell lines covering all mesothelioma subtypes and is an important regulator of motility, invasion, adhesion and in vivo tumor formation. However, our results indicate that EphA2 is not the major functional receptor for progranulin in mesothelioma cells, where progranulin activates a complex signaling network including EGFR and RYK. We further characterized progranulin mechanisms of action and demonstrated that progranulin, by modulating FAK activity, regulates the kinetic of focal adhesion disassembly, a critical step for cell motility. CONCLUSION: Collectively, our results highlight the complexity of progranulin oncogenic signaling in mesothelioma, where progranulin modulate functional cross-talks between multiple RTKs, thereby suggesting the need for combinatorial therapeutic approaches to improve treatments of this aggressive disease. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13046-022-02546-4. BioMed Central 2022-12-05 /pmc/articles/PMC9720952/ /pubmed/36471440 http://dx.doi.org/10.1186/s13046-022-02546-4 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Ventura, Elisa Xie, Christopher Buraschi, Simone Belfiore, Antonino Iozzo, Renato V. Giordano, Antonio Morrione, Andrea Complexity of progranulin mechanisms of action in mesothelioma |
title | Complexity of progranulin mechanisms of action in mesothelioma |
title_full | Complexity of progranulin mechanisms of action in mesothelioma |
title_fullStr | Complexity of progranulin mechanisms of action in mesothelioma |
title_full_unstemmed | Complexity of progranulin mechanisms of action in mesothelioma |
title_short | Complexity of progranulin mechanisms of action in mesothelioma |
title_sort | complexity of progranulin mechanisms of action in mesothelioma |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9720952/ https://www.ncbi.nlm.nih.gov/pubmed/36471440 http://dx.doi.org/10.1186/s13046-022-02546-4 |
work_keys_str_mv | AT venturaelisa complexityofprogranulinmechanismsofactioninmesothelioma AT xiechristopher complexityofprogranulinmechanismsofactioninmesothelioma AT buraschisimone complexityofprogranulinmechanismsofactioninmesothelioma AT belfioreantonino complexityofprogranulinmechanismsofactioninmesothelioma AT iozzorenatov complexityofprogranulinmechanismsofactioninmesothelioma AT giordanoantonio complexityofprogranulinmechanismsofactioninmesothelioma AT morrioneandrea complexityofprogranulinmechanismsofactioninmesothelioma |